CRYO Cryo-Save

 

TIDMCRYO 
 
RNS Number : 2736A 
Cryo-Save Group NV 
06 October 2009 
 

6 October 2009 
 
 
Cryo-Save Group NV 
 
 
New storage record - 7,300 samples stored in Q3 2009, 12% up on Q3 2008 and 4% 
up on Q2 2009 
 
 
Cryo-Save Group N.V. (AIM: CRYO, "Cryo-Save" or "the Group"), Europe's leading 
stem cell bank, has published its Q3 2009 sample storage numbers for the quarter 
to 30 September 2009. 
 
 
7,300 samples were stored in Q3 2009, up 12% over Q3 2008 (6,500 samples), and 
up 4% over Q2 2009 (7,000 samples). This is again an all time record for the 
Group. 
 
 
Since the introduction mid 2008 of the additional service to process and store 
stem cells from the umbilical cord itself, the Group has stored around 2,500 
cord samples. 
 
 
Separately the development of the processing and storage facility in Lyon, 
France is progressing. The Group aims to complete the installation, which will 
cost around EUR1 million, in early 2010. Subject to regulatory clearance, the 
Group expects to start using the Lyon facility in the first half of 2010. In the 
meantime Cryo-Save continues to sell its services to French customers via 
its Swiss operation. 
 
 
Marc Waeterschoot, Chief Executive, commented: 
 
 
"The positive trend set during the first half of this year has continued during 
the third quarter.  Although we were slightly impacted by the normal slower 
summer sales in our main markets in Southern Europe. 
 
 
"This growth compared to the second quarter, which was our best quarter ever, 
underpins our strong position for sustainable growth across a number of 
countries.  Coupled with the further roll out of our umbilical cord services to 
more countries and the expected growth of sales, especially in India and France, 
we remain confident for a good fourth quarter." 
 
 
 
 
+-------------------------------------+----------------------------------+ 
| For further details:                |                                  | 
+-------------------------------------+----------------------------------+ 
|                                     |                                  | 
+-------------------------------------+----------------------------------+ 
| Cryo-Save Group                     | + 31 (0) 575 548 998             | 
+-------------------------------------+----------------------------------+ 
| Marc Waeterschoot, Chief Executive  |                                  | 
| Arnoud van Tulder, Chief Financial  |                                  | 
| Officer                             |                                  | 
+-------------------------------------+----------------------------------+ 
|                                     |                                  | 
+-------------------------------------+----------------------------------+ 
| Daniel Stewart & Company plc        | + 44 (0) 20 7776 6550            | 
+-------------------------------------+----------------------------------+ 
| Simon Leathers                      |                                  | 
+-------------------------------------+----------------------------------+ 
|                                     |                                  | 
+-------------------------------------+----------------------------------+ 
| College Hill                        | + 44 (0) 20 7457 2020            | 
+-------------------------------------+----------------------------------+ 
| Adrian Duffield/Rozi Morris         |                                  | 
+-------------------------------------+----------------------------------+ 
 
 
About Cryo-Save 
With more than 115,000 samples saved, Cryo-Save is the leading stem cell bank in 
Europe and one of the fastest growing in the world. Driven by its international 
business strategy, Cryo-Save is now represented in 38 countries on three 
continents and has state-of-the-art processing facilities in Belgium, Germany, 
Dubai, India and France (under construction). 
Cryo-Save sets the highest quality standards in stem cell storage, as it aims to 
make an important contribution to conquer possible life-threatening diseases in 
the future. As a service to the public, Cryo-Save offers a Cost-free Family 
Donation Programme, free of charge, to families wishing to store their newborn's 
umbilical cord blood stem cells for a family member diagnosed with a 
life-threatening disease treatable by stem cells. The company is committed to 
further improve stem cell cryopreservation techniques, by participating in 
European Commission funded projects, in Universities and Hospitals. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCUUGUGUUPBGMA 
 

Cryo-Save (LSE:CRYO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Cryo-Save (LSE:CRYO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024